Tarolli, Sundheim, Covell & Tummino LLP
Treatment of IL-17 mediated disease by blocking SEFIR-SEFIR interactions
A method of treating an IL-17 mediated disease in a subject by administering to the subject a therapeutically effective amount of a of a cell-permeable decoy peptide that competitively inhibits binding of the SEFIR domain of IL-17R to the SEFIR domain of Act1. In particular, it has been determined that the αC helix region of the SEFIR domain of both IL-17R and Act1 plays an important role in the association of IL-17R and Act1. To facilitate cell permeation, the decoy peptide is preferably conjugated to a protein transduction domain. Examples of IL-17 mediated diseases include various human and animal inflammatory and autoimmune diseases such as asthma.
The Cleveland Clinic Foundation
C C C A C A C A A A
C07K C07K C07K A61P C07K A61K C07K A61K A61K A61K
inventional inventional additional inventional inventional additional additional inventional inventional inventional
Xiaoxia Junpeng Thomas A. Caini Jarod
Li Deng Hamilton Liu Zepp